SCHEMBL2197295

SCHEMBL2197295

C=Cc1ccccc1OCC(=O)OC1CC2CCC1C2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.46
RAB9A P51151 2/20 0.41
ATM Q13315 1/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.37
USP2 O75604 1/20 0.37
PKM P14618 1/20 0.35
KMT2A Q03164 1/20 0.35
CTSV O60911 1/20 0.35
CTSL P07711 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPC1 O15118 1/20 0.34
S1PR4 O95977 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
ITGA4 P13612 1/20 0.34
S1PR1 P21453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1397178 0.82 PTGDR2 (0.40) RAB9APTGDR2USP2ALDH1A1HPGD
SCHEMBL2196170 0.82 ATM (0.41) CYP19A1RAB9AATMCTSVCTSL
SCHEMBL7703171 0.81 CYP19A1 (0.54) CYP19A1RAB9AATMCTSVCTSL
SCHEMBL1397197 0.78 PTGDR2 (0.47) CYP19A1RAB9APTGDR2USP2KMT2A
SCHEMBL1397173 0.77 PDE4A (0.41) RAB9APDE4APDE4BPDE4CPDE4D
SCHEMBL1397154 0.77 GRM1 (0.45) CYP19A1RAB9AATMCTSVCTSL
SCHEMBL1397174 0.72 CYP19A1 (0.43) CYP19A1RAB9APTGDR2USP2KMT2A
SCHEMBL3364010 0.72 USP2 (0.39) PTGDR2USP2KMT2AALDH1A1LMNA
SCHEMBL1702936 0.71 HPGD (0.48) CYP19A1RAB9AATMPKMKMT2A
SCHEMBL28555380 0.71 ALDH1A1 (0.38) RAB9APTGDR2USP2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3253735-B1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2021-03-31 EP disclosed
US-20180009775-A1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2018-01-11 US disclosed
WO-2016124493-A1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2016-08-11 WO disclosed
EP-2197840-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2013-11-06 EP disclosed
EP-2197869-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2013-04-24 EP disclosed
EP-1472576-B1 SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2013-04-24 EP disclosed
EP-2197839-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2013-01-02 EP disclosed
EP-2349993-B1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2012-12-12 EP disclosed
US-20110171569-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2011-07-14 US disclosed
EP-1902019-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2010-07-07 EP disclosed
WO-2009047151-A1 SULPHONIUM SALT INITIATORS BASF SE (CH) 2009-04-16 WO disclosed
WO-2009047152-A1 SULPHONIUM SALT INITIATORS BASF SE (CH) 2009-04-16 WO disclosed
EP-1344109-B1 ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS CIBA HOLDING INC (CH) 2008-05-07 EP disclosed
EP-1595182-A2 HALOGENATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS Ciba SC Holding AG (CH) 2005-11-16 EP disclosed
WO-2004074242-A2 HALOGENATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-09-02 WO disclosed
EP-1344109-A2 ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS Ciba SC Holding AG (CH) 2003-09-17 EP disclosed
EP-1320785-A2 OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS Ciba SC Holding AG (CH) 2003-06-25 EP disclosed
WO-2002046507-A2 ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-06-13 WO disclosed
WO-2002025376-A2 OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-03-28 WO disclosed
US-6261738-B1 LATENT CURING CATALYSTS FOR PHOTORESISTS SUCH AS 2,2,2-TRIFLUORO-1-PHENYL-ETHANONE OXIME-O-METHYL SULFONATE CIBA SPECIALTY CHEMICALS CORPORATION 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180009775-A1 LATENT ACIDS AND THEIR USE LTA, C1S, C9 CYP19A1 355/4885RAB9A 2074/4885ATM 3063/4885
US-20110171569-A1 SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS NR2E3, HCAR3, HRH4 CYP19A1 1750/4885RAB9A 4259/4885ATM 1725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.